Acelyrin Cash Flow Statement

Financials in millions CAD. Fiscal year is July - June.

Millions CAD. Fiscal year is Jul - Jun.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Mar '25 Mar 31, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022
Net Income	-0.38	-0.52	-0.49	-0.19
Loss (Gain) From Sale of Investments	0.07	-0.05	-	-
Stock-Based Compensation	0.02	0.11	0.1	0.01
Other Operating Activities	-0.01	-0.01	-	-
Change in Accounts Receivable	0	-0.01	-0.02	-
Change in Accounts Payable	-0.01	0.06	0.05	-
Change in Other Net Operating Assets	0.01	0.01	0.04	-0.07
Operating Cash Flow	-0.29	-0.41	-0.33	-0.25
Capital Expenditures	-	-	-0.14	-0.54
Sale of Property, Plant & Equipment	-	0.14	-	-
Investing Cash Flow	-	0.14	-0.14	-0.54
Issuance of Common Stock	0.01	0.27	0.64	1.15
Financing Cash Flow	0.01	0.27	0.64	1.15
Net Cash Flow	-0.28	-0.01	0.18	0.36
Free Cash Flow	-0.29	-0.41	-0.46	-0.79
Free Cash Flow Per Share	-0.01	-0.01	-0.01	-0.06
Levered Free Cash Flow	-0.2	-0.25	-0.28	-
Unlevered Free Cash Flow	-0.2	-0.25	-0.28	-
Change in Working Capital	0	0.06	0.07	-0.07

Source: S&P Global Market Intelligence. Standard template. Financial Sources.